Acrobiosystems Co

Acrobiosystems Co Current Liabilities

The Current Liabilities of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 84.97 M CNY. In the previous year, Current Liabilities was 172.14 M CNY — a change of -50.64% (lower).

Current Liabilities

84.97 MCNY

YoY

-50.64%

Last updated:

Current Liabilities of Acrobiosystems Co is 2025 84.97 M CNY. Current Liabilities of Acrobiosystems Co was 2024 172.14 M CNY. It decreases by -50.64% lower compared to the previous year.

The Acrobiosystems Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
10.16 M CNY
Jan 1, 2019
12.72 M CNY
Jan 1, 2020
11.83 M CNY
Jan 1, 2021
44.80 M CNY
Jan 1, 2022
81.25 M CNY
Jan 1, 2023
162.15 M CNY
Jan 1, 2024
172.14 M CNY
Jan 1, 2025
84.97 M CNY
The Acrobiosystems Co Current Liabilities history
YEARCurrent LiabilitiesYoY
84.97 MCNY-50.64%
172.14 MCNY+6.16%
162.15 MCNY+99.57%
81.25 MCNY+81.37%
44.80 MCNY+278.56%
11.83 MCNY-6.93%
12.72 MCNY+25.13%
10.16 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Current Liabilities of Acrobiosystems Co is 84.97 M CNY in 2025.

Current Liabilities of Acrobiosystems Co changed from 172.14 M CNY to 84.97 M CNY, representing a -50.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co